All In Biotech

Drug Trial Radar · NCT06150183

Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

A First-in-Human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of BNT314 as Monotherapy in Patients With Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

41

Actual

Start

Nov 30, 2023

Primary completion

Aug 18, 2026

Study completion Nov 2026

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Genmab
First posted
Nov 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer. This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose will be investigated.

Conditions

  • Advanced Malignant Solid Tumor

Interventions

  • BNT314Biological

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of dose-limiting toxicity within a cohortTime frame: 21 days from the first dose administration
  2. Number and percentage of patients with occurrence of treatment-emergent adverse events (TEAEs) including Grade ≥ 3, serious, fatal TEAE by relationshipTime frame: from first dose of study treatment to 90 days after last dose of study treatment
  3. Number and percentage of patients with occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) due to TEAETime frame: from first dose of study treatment to 90 days after last dose of study treatment
  4. Number and percentage of patients with occurrence of Grade ≥ 3 abnormal safety laboratory parametersTime frame: from first dose of study treatment to 90 days after last dose of study treatment

Locations

14 sites in 6 countries. Site status is shown where the registry gives one.

  • START Midwest

    Grand Rapids, Michigan

  • Carolina BioOncology Institute, LLC

    Huntersville, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • GZA Ziekenhuizen

    Antwerp, Belgium

  • CHU de Liège

    Liège, Belgium

  • Rigshospitalet

    Copenhagen, Denmark

  • National Cancer Center Hospital East

    Kashiwanoha, Japan

  • Hospital Quironsalud Barcelona (NEXT Barcelona)

    Barcelona, Spain

  • Hospital Fund. Jiménez Dia

    Madrid, Spain

  • Hospital HM Univ. Sanchinarro, Ensayos START

    Madrid, Spain

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Royal Marsden Hospital - London

    London, United Kingdom

  • The Christie Hospital

    Manchester, United Kingdom

  • Northern Centre for Cancer Care

    Newcastle, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.